Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ID Biomedical - Elephant Hunting?? (IDBEF) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (5)	1/30/1999 1:58:00 AM
From: Kaiser Soza	Respond to of 27

Hi Steve, I understand they will sell off the rights to CPT on a royalty basis to various companies based on the specific type of test application. The "ultimate" test of the CPT technology is evidently the detection of TB in a fast, cost efficient manner. When the stock had its huge run to $34 (pre-split) they had proven the technology worked, problem was it only worked in a petrie dish, not in real life environments like sputum samples. The sensitivity and specificity needed to be improved. Rather than simply work on the TB, they began to look for ready markets in detection of "easier" targets. They signed a bunch of research agreements with various companies for specific applications, focusing on the most profitable market segments. After this, they acquired the TB vaccine technology, thinking that they better cover themselves off on both sides, detection and possible prevention!! The company maintains they will be profitable next year. Check out the news release today. Regards, Kaiser..